Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	USD 0.3701	+11.14%	46,712,208
09/07/26	USD 0.3330	+0.48%	22,369,667
08/07/26	USD 0.3314	-4.08%	224,250
07/07/26	USD 0.3455	+0.03%	149,231
06/07/26	USD 0.3454	+0.41%	167,885

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3701USD

Average target price

1.500USD

Spread / Average Target

+305.30%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 06:00:00 11/07/26 am AEST			5-day change	1st Jan Change
0.3701 ^USD	+11.14%		+7.59%	-27.43%

10/07	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI

Market Cap	15.04M 13.15M 12.13M 11.21M 21.26M 1.43B 21.62M 145M 56.93M 707M 56.46M 55.23M 2.43B	P/E 2026 *	-1.23x	P/E 2027 *	-6.17x
Enterprise Value	15.04M 13.15M 12.13M 11.21M 21.26M 1.43B 21.62M 145M 56.93M 707M 56.46M 55.23M 2.43B	EV / Sales 2026 *	2.94x	EV / Sales 2027 *	0.87x
Free-Float	86.69%	Yield 2026 *	-	Yield 2027 *	-

10/07	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
30/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
30/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
16/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
31/03	Scienture reports year end 2025 financial results and provides business update	RE
30/03	Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/03	Scienture Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI

15/08/25	Top Midday Decliners	MT
01/06/23	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
29/03/23	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
11/05/22	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
30/03/22	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

Scienture Holdings, Inc. Stock

Stocks

SCNX

US80880X1046

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news : Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Course Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

09/07	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers	AQ
18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ
09/06	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team	AQ
04/06	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC	AQ
02/06	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041	AQ

1 day	+11.14%
1 week	+7.59%
Current month	+5.74%
1 month	+4.90%
3 months	+11.14%
6 months	-33.92%
Current year	-27.43%

1 week	0.29	0.38
1 month	0.29	0.43
Current year	0.24	0.64
1 year	0.24	2.6
3 years	0.24	13.42
5 years	0.24	13.42
10 years	0.24	13.42

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/09/24	Narasimhan Mani	Conversion	Director	2,927,538	167.2839%
19/09/24	Shankar Hariharan	Conversion	Chief Executive Officer	3,853,296	220.1831%
25/07/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	+11.14%	+7.59%	-77.43%	-	15.04M
MCKESSON CORPORATION	+1.66%	+2.50%	+12.79%	+94.32%	94.36B
CARDINAL HEALTH, INC.	+0.87%	-1.31%	+45.40%	+151.68%	55.23B
SIGMA HEALTHCARE LIMITED	-1.74%	+1.08%	-1.05%	+256.96%	22.56B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+0.37%	+0.06%	-13.74%	-24.70%	8.01B
HUADONG MEDICINE CO., LTD	+1.98%	-2.23%	-26.26%	-33.33%	7.6B
SINOPHARM GROUP CO. LTD.	+0.42%	-0.06%	-10.63%	-29.41%	6.66B
H. LUNDBECK A/S	-1.16%	-1.48%	+23.13%	+31.93%	6.25B
GALENICA AG	-0.23%	+0.41%	-1.70%	+22.88%	5.36B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+0.20%	+1.42%	-5.83%	-8.33%	3.68B
Average	+1.35%	-1.08%	-5.53%	+51.33%	20.97B
Weighted average by Cap.	+0.85%	-0.33%	+16.32%	+108.33%

	2026 *	2027 *
Net sales	5.12M 4.48M 4.13M 3.82M 7.24M 489M 7.37M 49.39M 19.39M 241M 19.24M 18.82M 827M	17.22M 15.06M 13.89M 12.83M 24.34M 1.64B 24.75M 166M 65.18M 809M 64.64M 63.24M 2.78B
Net income	-12.52M -10.95M -10.1M -9.33M -17.7M -1.19B -18M -121M -47.39M -588M -47M -45.98M -2.02B	-2.81M -2.46M -2.27M -2.1M -3.98M -268M -4.05M -27.13M -10.65M -132M -10.57M -10.34M -455M
Net Debt	-	-